A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis, Active and recruiting

**Study Purpose:** The purpose of the study is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (gMG).

**Recruitment Information:**
- Study Type: randomized
- Status: recruiting
- Target Patient: Male and female adult patients with gMG
- Eligible Ages: adults (at least 18 years old)

Link to appropriate websites: ClinicalTrials.gov Identifier: NCT03971422

For more information, a pre-screener and locations, please see: www.MycarinGstudy.com

**Key Inclusion Criteria:**
- Study participant must be ≥18 years of age, at the time of signing the informed consent
- Study participant has documented diagnosis of MG at Visit 1, based on study participant's history and supported by previous evaluations
- Study participant has a confirmed positive record of autoantibodies against acetylcholine receptor (ACHR) or muscle-specific kinase (MuSK) prior to Visit 1
- Study participant has Myasthenia Gravis Foundation of America (MGFA) Class II to IVa at Visit 1
- Study participant with a myasthenia gravis-activities of daily living (MG-ADL) score of at least 3 AND a quantitative myasthenia gravis (QMG) score of at least 11 at Visit 1 and at Baseline

**Key Exclusion Criteria:**
- Study participant has a clinically relevant active infection (eg, sepsis, pneumonia, or abscess) in the opinion of the Investigator, or had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior to the first dose of investigational medicinal product (IMP)
- Study participant has experienced hypersensitivity reaction after exposure to other anti-neonatal Fc receptor (FcRn) drugs
Study participant with severe (defined as Grade 3 on the MG-ADL scale) weakness affecting oropharyngeal or respiratory muscles, or who has myasthenic crisis or impending crisis at Visit 1

**Study Information:**

Sponsor: UCB Biopharma SPRL  
Principal Investigator: TBD  
Study Coordinator: TBD  
Type of Study: Multi-center Study  
Duration: 18 weeks  
Single Center/Multi-center: Multi-center  
Travel Funds Available: ☒ Y ☐ N